1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms E Walmsley
|
|||
b)
|
Position/status
|
Chief Executive Officer
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature of the
transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2016 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.0000
|
32,596
(Deferred)
|
|
||
|
£0.0000
|
19,234
(Matching)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated volume
Price
|
51,830
£0.0000
|
||||
e)
|
Date
of the transaction
|
2019-02-18
|
|||
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms E Walmsley
|
|||
b)
|
Position/status
|
Chief Executive Officer
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature of the
transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 18 February 2019 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.756
|
15,345 (Deferred)
|
|
||
|
£15.756
|
9,053 (Matching)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated volume
Price
|
24,398
£15.756
|
||||
e)
|
Date
of the transaction
|
2019-02-18
|
|||
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Connor
|
|||
b)
|
Position/status
|
President, Global Vaccines
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature of the
transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2016 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.0000
|
11,073
(Deferred)
|
|
||
|
£0.0000
|
6,534
(Matching)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated volume
Price
|
17,607
£0.0000
|
||||
e)
|
Date
of the transaction
|
2019-02-18
|
|||
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Connor
|
|||
b)
|
Position/status
|
President, Global Vaccines
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 18 February 2019 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.756
|
5,218
(Deferred)
|
|
||
|
£15.756
|
3,079
(Matching)
|
|
||
|
|
|
|
||
d)
|
Aggregated information
|
|
|||
Aggregated volume
Price
|
8,297
£15.756
|
||||
e)
|
Date
of the transaction
|
2019-02-18
|
|||
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
|||
|
|
|
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr S Dingemans
|
|||
b)
|
Position/status
|
Chief Financial Officer
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature of the
transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2016 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.0000
|
43,044
(Deferred)
|
|
||
|
£0.0000
|
25,398
(Matching)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated volume
Price
|
68,442
£0.0000
|
||||
e)
|
Date
of the transaction
|
2019-02-18
|
|||
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr S Dingemans
|
|||
b)
|
Position/status
|
Chief Financial Officer
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 18 February 2019 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.716
|
20,263 (Deferred)
|
|
||
|
£15.716
|
11,955
(Matching)
|
|
||
|
|
|
|
||
d)
|
Aggregated information
|
|
|||
Aggregated volume
Price
|
32,218
£15.716
|
||||
e)
|
Date
of the transaction
|
2019-02-18
|
|||
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr P Thomson
|
|||
b)
|
Position/status
|
President, Global Affairs
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature of the
transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 11
February 2016 under the Company's 2009 Deferred Annual Bonus Plan -
Deferred Bonus and Matching Awards.
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.0000
|
9,064
(Deferred)
|
|
||
|
£0.0000
|
5,349
(Matching)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated volume
Price
|
14,413
£0.0000
|
||||
e)
|
Date
of the transaction
|
2019-02-18
|
|||
f)
|
Place of the
transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr P Thomson
|
|||
b)
|
Position/status
|
President, Global Affairs
|
|||
c)
|
Initial
notification/ amendment
|
Initial Notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 18 February 2019 under
the Company's Deferred Annual Bonus Plan - Deferred Bonus and
Matching Awards.
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7215
|
4,271 (Deferred)
|
|
||
|
£15.7215
|
2,521
(Matching)
|
|
||
|
|
|
|
||
d)
|
Aggregated information
|
|
|||
Aggregated volume
Price
|
6,792
£15.7215
|
||||
e)
|
Date
of the transaction
|
2019-02-18
|
|||
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
19, 2019
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|